Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 61
- Registration Number
- NCT00124059
- Locations
- 🇺🇸
University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States
Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-06-10
- Target Recruit Count
- 15
- Registration Number
- NCT00122070
- Locations
- 🇺🇸
University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine - Department of Psychiatry, Cherry Hill, New Jersey, United States
Seroquel in Bipolar Depression Versus SSRI
- Conditions
- Bipolar DisorderBipolar DepressionDepression
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 676
- Registration Number
- NCT00119652
- Locations
- 🇹🇷
Research Site, Manisa, Turkey
Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder
- Conditions
- Bipolar I DisorderAlcohol Dependence
- First Posted Date
- 2005-06-17
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00114686
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder
- Conditions
- Anxiety Disorder
- Interventions
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00113295
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
- Conditions
- Bipolar I Disorder
- First Posted Date
- 2005-04-08
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 710
- Registration Number
- NCT00107731
- Locations
- 🇬🇧
Research Site, Welwyn Garden City, United Kingdom
Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients
- Conditions
- Bipolar Disorder
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2011-05-24
- Target Recruit Count
- 30
- Registration Number
- NCT00097032
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 249
- Registration Number
- NCT00090324
- Locations
- 🇺🇦
Research Site, Odessa, Ukraine
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania
- Conditions
- Bipolar Disorder
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 220
- Registration Number
- NCT00090311
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 340
- Registration Number
- NCT00090012
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waco, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.